Apomorphine or ropinirole? New data refine canine emesis choices

Version 1

A new head-to-head evidence base is sharpening the choice between apomorphine and ropinirole when veterinarians need to induce emesis in dogs. Ropinirole ophthalmic solution, marketed as Clevor, became the first FDA-approved emetic for dogs in June 2020, offering a topical option that avoids injection and achieved vomiting in 95% of dogs within 30 minutes in its registration study. More recent comparative data, though, complicate the picture: a 2023 clinical report found ropinirole had similar overall efficacy to apomorphine for removing toxic or foreign gastric material, while 2025 studies split on performance, with one healthy-dog trial finding the two agents equally effective overall and one prospective randomized ER study at two referral hospitals finding apomorphine delivered better first-dose success, faster onset, fewer minor adverse events, and less prolonged vomiting or need for antiemetic rescue after toxin or foreign-body ingestion. (fda.gov)

Why it matters: For veterinary professionals, this is less about a single winner and more about matching the drug to the case. Ropinirole brings the advantage of an FDA-approved canine label and easy ophthalmic administration, but it can cause transient ocular irritation and may take longer or require repeat dosing if vomiting does not occur within 20 minutes. Apomorphine remains extra-label in U.S. dogs, yet clinicians and toxicology resources continue to favor it when rapid decontamination is the priority, especially in emergency presentations involving recent toxin or foreign-body exposure. (vetmed.illinois.edu)

What to watch: Expect more discussion around protocol selection in ER and GP settings as clinicians weigh labeled use and convenience against speed, repeat-dose needs, adverse-event profiles, and rescue-treatment requirements in real-world emergency patients. (vetmed.illinois.edu)